How Has the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Evolved Historically and What is its Current Size?
The sodium glucose cotransporter 2 (sglt2) inhibitors market has seen considerable growth due to a variety of factors.
• The sodium glucose cotransporter 2 (SGLT2) inhibitors market has grown significantly in recent years. It will increase from $10.17 billion in 2024 to $11.07 billion in 2025 at a CAGR of 8.8%.
This growth is attributed to early success in clinical trials, rising regulatory approvals, increased diabetes diagnoses, and a growing demand for innovative treatments for diabetes.
What Is The Projected Growth Of The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Template Market?
The sodium glucose cotransporter 2 (sglt2) inhibitors market is expected to maintain its strong growth trajectory in upcoming years.
• The sodium glucose cotransporter 2 (SGLT2) inhibitors market is expected to grow strongly, reaching $15.4 billion by 2029 at a CAGR of 8.6%.
This growth is fueled by rising diabetes prevalence, increasing obesity rates, greater awareness of diabetes management, and expanding applications in heart and kidney disease treatments. Key trends include combination therapies, personalized medicine, technological improvements, and traditional drug development.
What Are The Key Drivers Fueling Growth In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
Expectations for the sodium glucose cotransporter 2 (SGLT2) inhibitor market's growth are heightened due to the escalating incidence of diabetes. This metabolic disorder, characterized by elevated blood sugar levels, originates from insulin secretion or insulin action defects, or possibly both. Various factors such as urbanization, stress, environmental pollutants, and inadequate access to healthcare incite a rise in diabetes. Diabetes management employs SGLT2 inhibitors to diminish blood glucose levels by flushing glucose out in urine instead of it being reabsorbed by the kidneys. These inhibitors also provide cardiovascular and renal benefits, proving to be critical for controlling diabetes and its associated complications. As reported by the Australian Bureau of Statistics in December 2023, approximately 5.3% or 1.3 million Australians were found to have diabetes in 2022, with similar rates observed in males (5.8%) and females (4.9%). Diabetes rates exhibit an upward trend, notably spiking with increasing age, amounting to 18.7% among those aged 75 or above. The most prevalent form is Type 2 diabetes, contributing to 87.6% of the cases. Other risk factors include being born overseas, living in disadvantaged areas, and having a disability, which contribute to high diabetes rates. This growing incidence of diabetes consequently propels the sodium glucose cotransporter 2 (SGLT2) inhibitor market's expansion.
What Are The Principal Market Segments In The Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry?
The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented –
1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
2) By Route Of Administration: Oral Route, Other Route Of Administration
3) By End User: Hospitals, Homecare Settings, Clinics
Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure
Pre-Book The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
Leading firms in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are concentrating their efforts on creating dual inhibitor therapeutic formulas. These are tailored to enhance patient results and control blood sugar levels. Dual inhibitor therapies focus on two distinct sodium-glucose cotransporters (SGLT1 and SGLT2) simultaneously to improve effectiveness in handling afflictions like heart failure and diabetes. For instance, in May 2023, Lexicon Pharmaceuticals Inc., an American biopharmaceutical corporation, got approval from the Food and Drug Administration (FDA) for a medicine for heart failure named sotagliflozin. This pioneering dual inhibitor of sodium-glucose cotransporters 1 and 2 is a daily tablet aimed at lowering cardiovascular mortality, hospital admissions due to heart failure, and urgent heart failure visits in grown-ups dealing with heart failure, type 2 diabetes, chronic kidney disease and other cardiovascular risk factors. It brings about benefits via decreased renal glucose and sodium reabsorption, ultimately lessening preload and afterload and reducing sympathetic activity.
Who Are the Key Players In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are:
• Pfizer Inc.
• Johnson & Johnson Inc.
• Merck & Co. Inc.
• Bayer AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmBH
• Astellas Pharma Inc
• Daiichi Sankyo Company Limited
• Sun Pharmaceutical Industries Ltd
• Sumitomo Dainippon Pharma Co. Ltd.
• Taisho Pharmaceutical Holdings Co. Ltd.
• Lupin Limited
• Glenmark pharmaceuticals
• Torrent Pharmaceuticals Ltd
• Mankind Pharma Ltd
• Kissei Pharmaceutical Co. Ltd.
• Patsnap Synapse
• Kotobuki Pharmaceutical Co Ltd.
What Are The Regional Insights Into The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
